Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories Inc. Class A

Biome Australia Ltd ( ($AU:BIO) ) has issued an update. Biome Australia has received ethics approval from La Trobe University’s Human Research Ethi...

Biome Australia Secures Ethics Approval for First Human Trial of Proprietary Probiotic BMB18

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Dan...

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Danaher (DHR) and BridgeBio Pharma (BBIO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Perspective Therapeutics (CATX – Research Report), Z...

Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Zenas BioPharma, Inc. (ZBIO)

The latest announcement is out from Sabio Holdings ( ($TSE:SBIO) ). Sabio Holdings has been named winner of the Best Workspace category and a final...

Sabio Wins WorkLife Award Honors and Hires Atrium for Sponsored Research Coverage

Berenberg Bank analyst Harry Gillis maintained a Buy rating on Swedish Orphan Biovitrum AB yesterday and set a price target of SEK420.00. The compa...

Berenberg Bank Remains a Buy on Swedish Orphan Biovitrum AB (0MTD)

BB Biotech ( ($CH:BION) ) just unveiled an update. BB Biotech AG expects to report an unaudited profit of around CHF 578 million for the 2025 finan...

BB Biotech Forecasts Surge in 2025 Profit to CHF 578 Million

BB Biotech ( ($CH:BION) ) just unveiled an announcement. BB Biotech AG reported a sharp turnaround in 2025 with a preliminary net profit of CHF 578...

BB Biotech posts strong 2025 rebound and lifts dividend after biotech outperformance

BioVaxys Technology ( ($TSE:BIOV) ) just unveiled an update. BioVaxys reported positive preliminary data from its investigator-initiated Phase 1b/2...

BioVaxys Cancer Vaccine Combo Shows Durable Responses in Recurrent Ovarian Cancer Trial

Mindbio Therapeutics Corp. ( ($TSE:MBIO) ) just unveiled an update. MindBio Therapeutics has listed its common shares for trading on the OTCQB Mark...

MindBio Therapeutics Lists on OTCQB as It Pushes Voice-Based AI Intoxication Tech in US Market

Mindbio Therapeutics Corp. ( ($TSE:MBIO) ) has issued an announcement. MindBio Therapeutics has listed its common shares for trading on the OTCQB M...

MindBio Therapeutics Lists on OTCQB as It Expands AI Voice Intoxication Platform in US Market

BioVaxys Technology ( ($TSE:BIOV) ) has provided an announcement. BioVaxys Technology is advancing a series of collaborations and non-dilutive fund...

BioVaxys Advances DPX Vaccine Platform With New Collaborations and Positive Trial Data

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is down 0.29% in pre-market trading on Wednesday after fall...

Vanguard Total Stock Market ETF (VTI) Daily Update—1/15/25

Crescent Biopharma, Inc. ($CBIO) announced an update on their ongoing clinical study. Study Overview Crescent Biopharma, Inc. has launched a new ea...

Crescent Biopharma Advances CR-001 Cancer Trial Into First-in-Human Stage

An announcement from Fortress Biotech ( ($FBIO) ) is now available. On January 13, 2026, Fortress Biotech and its majority-owned subsidiary Cyprium...

Fortress Biotech Gains FDA Approval for Menkes Treatment

Evercore ISI analyst Cory Kasimov maintained a Buy rating on BridgeBio Pharma today and set a price target of $100.00. According to TipRanks, Kasim...

Evercore ISI Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

Raymond James analyst Martin Auster reiterated a Buy rating on BridgeBio Pharma today and set a price target of $85.00. According to TipRanks, Aust...

BridgeBio Pharma (BBIO) Gets a Buy from Raymond James

The latest update is out from Ibio ( ($IBIO) ). On January 8, 2026, iBio, Inc. entered into a securities purchase agreement with existing, healthca...

iBio Announces Private Placement to Fund Pipeline Expansion

The latest announcement is out from BioAge Labs, Inc. ( ($BIOA) ). On January 12, 2026, BioAge Labs reported additional positive interim Phase 1 da...

BioAge Labs advances BGE-102 with strong Phase 1 data

An update from Xenetic Biosciences ( ($XBIO) ) is now available. On December 11, 2025, Xenetic Biosciences, Inc. announced that its 2025 Annual Mee...

Xenetic Biosciences faces ongoing delays in annual meeting

Barclays analyst Matt Miksic maintained a Buy rating on Orchestra BioMed Holdings today and set a price target of $12.00. According to TipRanks, Mi...

Orchestra BioMed Holdings (OBIO) Receives a Buy from Barclays

BioVersys AG ($CH:BIOV) announced an update on their ongoing clinical study. BioVersys AG has announced a new Phase 3 trial designed to test its an...

BioVersys Advances BV100 Into Phase 3 For Drug-Resistant Hospital Pneumonia: What Investors Should Watch

Mindbio Therapeutics Corp. ( ($TSE:MBIO) ) has shared an update. MindBio Therapeutics Corp. announced that CEO Justin Hanka will present at the 9th...

MindBio Showcases AI Voice-Based Intoxication Tech at Major Neuroscience Forum

In a report released today, Andrew Tsai from Jefferies maintained a Buy rating on BridgeBio Pharma, with a price target of $85.00. Tsai covers the ...

Jefferies Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

Amid global market ups and downs, TipRanks provides useful tools to help investors make decisions. One of its most powerful tools is the Smart Scor...

3 Stocks with a ‘Perfect 10’ Smart Score

Swedish Orphan Biovitrum AB ( ($SE:SOBI) ) just unveiled an announcement. Sobi announced that topline phase 2a data from the EMBRACE trial of Gamif...

Sobi Advances Gamifant After Positive Phase 2a Data in Interferon-Gamma–Driven Sepsis

Wells Fargo analyst Tiago Fauth maintained a Buy rating on BridgeBio Pharma yesterday and set a price target of $84.00. The company’s shares closed...

Wells Fargo Keeps Their Buy Rating on BridgeBio Pharma (BBIO)

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Zenas BioPharma, Inc. today and set a price target of $55.00. Kasimov covers the Healt...

Evercore ISI Keeps Their Buy Rating on Zenas BioPharma, Inc. (ZBIO)

Bank of America Securities analyst Jason Zemansky maintained a Buy rating on BridgeBio Pharma today and set a price target of $85.00. Zemansky cove...

Bank of America Securities Remains a Buy on BridgeBio Pharma (BBIO)

Zenas BioPharma, Inc. ( ($ZBIO) ) has shared an update. On January 5, 2026, Zenas BioPharma reported positive top-line data from its global, regist...

Zenas BioPharma Announces Positive Phase 3 Obexelimab Results

Jade Biosciences ( ($JBIO) ) has issued an announcement. On January 5, 2026, Jade Biosciences announced its 2026 strategic priorities ahead of the ...

Jade Biosciences Outlines 2026 Autoimmune Pipeline Priorities

Biome Australia Ltd ( ($AU:BIO) ) just unveiled an update. Biome Australia reported record sales for the second quarter and first half of FY26, wit...

Market Cap	$8.03B	P/E Ratio	29.80
52W High	$358.40	52W Low	$211.43
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	-35.0%	52W Position	58.5%
Overall Score	44	Value Score	50
Quality Score	57	Technical Score	25

EPS Current Est	$9.98	EPS Next Est	$10.36
EPS Growth Est	+3.8%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BIO	$297.43	+1.27%	159.00K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BIO	$297.43	+1.3%	159.00K
3
4
5
6

BIO

BIO

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Bio-Rad Laboratories Inc. Class A Data in Excel

Get Bio-Rad Laboratories Inc. Class A Data in Excel